Rethink dosing and
Just 1 subcutaneous self-injection every 2 weeks1
Support patients with information on self-administration
TAKHZYRO is intended for self-administration or administration by a caregiver after being trained by a healthcare professional.1 In clinical studies, the majority of patients self-administered TAKHZYRO within 10 to 60 seconds.1 You can use the FDA-approved Instructions For Use information below to show patients the proper way to administer TAKHZYRO. And let patients know they can refer to supplementary injection training materials to reinforce your instructions:
‡Timing is dependent upon when the forms are received by OnePath®. The Quick Start Program is available to all commercially insured patients ≥12 years of age who are US residents with a confirmed diagnosis of HAE. Takeda and its affiliates reserve the right to change or discontinue this program at any time, without notice. Void where prohibited by law. This program does not constitute a financial assistance program.